Results 91 to 100 of about 46,198 (239)

The role of social determinants of health in hydroxyurea adherence among persons with sickle cell disease: A systematic review

open access: yesJournal of the Georgia Public Health Association
Objective: Georgia has one of the highest prevalences of sickle cell disease (SCD). For Georgians living with SCD, inadequate medication adherence is associated with important clinical outcomes.
Doreen O Ugwu   +6 more
doaj   +1 more source

Hydroxyurea therapy for neurological and cognitive protection in pediatric sickle cell anemia in Uganda (BRAIN SAFE II): Protocol for a single-arm open label trial

open access: yesContemporary Clinical Trials Communications
Background: Children with sickle cell anemia (SCA) in Sub-Saharan Africa are at high risk of sickle cerebrovascular injury (SCVI). Hydroxyurea, a commonly used disease-modifying therapy, may reduce SCVI resulting in potential impact on reducing stroke ...
Vincent Mboizi   +13 more
doaj   +1 more source

Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes Claros

open access: yesRevista Brasileira de Hematologia e Hemoterapia, 2011
BACKGROUND: The development of therapies for sickle cell disease has received special attention, particularly those that reduce the polymerization of hemoglobin S.
Fernanda Kelle de Souza Santos   +1 more
doaj   +1 more source

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

open access: yesBritish Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka   +3 more
wiley   +1 more source

Compromised DNA replication in gut cells underlies sensitivity to genotoxic stress in the tardigrade Hypsibius exemplaris

open access: yesThe FEBS Journal, EarlyView.
DNA damage in the tardigrade Hypsibius exemplaris elicits distinct cellular outcomes depending on replication status. While non‐replicating cells tolerate genotoxic stress, constitutively replicating cells undergo irreversible replication failure upon DNA damage, leading to loss of tissue homeostasis, fat depletion, sterility, and organismal death ...
Gonzalo Quiroga‐Artigas   +4 more
wiley   +1 more source

Role of hydroxyurea therapy in the prevention of organ damage in sickle cell disease: a systematic review and meta-analysis

open access: yesSystematic Reviews
Background Hydroxyurea is an affordable drug that reduces vaso-occlusive crises and transfusion requirements in sickle cell disease. However, its effectiveness in preventing chronic organ damage is still unclear.
Naveen Khargekar   +6 more
doaj   +1 more source

Blood Cell Counts and the Duffy Null Phenotype: Beyond Neutropenia

open access: yesInternational Journal of Laboratory Hematology, EarlyView.
ABSTRACT The absence of Duffy antigen expression on red blood cells, caused by a single nucleotide polymorphism in the DARC/ACKR1 gene, confers protection against malaria and is associated with lower absolute neutrophil counts (ANC) in some studied populations.
Elvira Deolinda R. P. Velloso   +11 more
wiley   +1 more source

Hydroxyurea transport across the blood-brain and blood-cerebrospinal fluid barriers of the guinea-pig

open access: yes, 2003
Hydroxyurea is used in the treatment of HIV infection in combination with nucleoside analogues, 2′3′-didehydro-3′ deoxythymidine (D4T), 2′3′-dideoxyinosine or abacavir.
Gibbs, J. E.; id_orcid   +6 more
core   +1 more source

A Pharmacist-Managed Hydroxyurea Prescribing Protocol Improves Uptake and Optimization among Patients with Sickle Cell Disease

open access: yesAdvances in Hematology
Sickle cell disease (SCD) is a common genetic disorder with potentially serious sequelae that can be effectively treated with hydroxyurea. Despite its favorable benefit-risk profile, hydroxyurea uptake in patients with SCD is low.
Cameron Roessner   +4 more
doaj   +1 more source

Survival and mortality among users and non-users of hydroxyurea with sickle cell disease

open access: yesRevista Latino-Americana de Enfermagem, 2015
OBJECTIVE: to estimate survival, mortality and cause of death among users or not of hydroxyurea with sickle cell disease.METHOD: cohort study with retrospective data collection, from 1980 to 2010 of patients receiving inpatient treatment in two Brazilian
Olinda Maria Rodrigues de Araujo   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy